Comparison of sirolimus‐eluting stent and paclitaxel‐eluting stent for long‐term cardiac adverse events in diabetic patients: The Korean multicenter angioplasty team (KOMATE) registry |
| |
Authors: | Jung‐Sun Kim MD PhD Byoung Ho Lee MD Young‐Guk Ko MD Donghoon Choi MD PhD Yangsoo Jang MD PhD FACC Pil‐Ki Min MD Young‐Won Yoon MD PhD Bum Kee Hong MD PhD Hyuck Moon Kwon MD PhD Min‐Soo Ahn MD Seung‐Hwan Lee MD PhD Jung Han Yoon MD PhD Byoung Kwon Lee MD PhD Byung Ok Kim MD PhD Byeong‐Kuk Kim MD PhD Sung Jin Oh MD Dong Woon Jeon MD Joo Young Yang MD PhD Jung Rae Cho MD Jae‐Hun Jung MD Seung‐Ki Ryu MD |
| |
Affiliation: | 1. Yonsei Cardiovascular Center, Seoul, Republic of Korea;2. Yongdong Severance Hospital, Seoul, Republic of Korea;3. Wonju Christian Hospital, Wonju, Republic of Korea;4. Sanggye Paik Hospital, Seoul, Republic of Korea;5. NHIC Ilsan Hospital, Goyang, Republic of Korea;6. Kangnam Sacred Heart Hospital, Seoul, Republic of Korea;7. Nowon Eulji Hospital, Seoul, Republic of Korea |
| |
Abstract: | Background: There is some controversy on long‐term cardiac outcomes between sirolimus‐eluting stents (SES) and paclitaxel‐eluting stents (PES) in diabetes mellitus (DM). We compared cardiac adverse events after SES and PES implantation in patients with DM over a period of 3 year. Methods: A total of 634 patients with DM treated with SES (n = 428) or PES (n = 206) were consecutively enrolled in the KOMATE registry from 2003 to 2004. We assessed major adverse cardiac events (MACEs, cardiovascular death, nonfatal myocardial infarction, ischemia driven target vessel revascularization) and stent thrombosis (ST) according to the definitions set by the Academic Research Consortium. Results: Propensity score (PS) analysis was performed to adjust different baseline characteristics. The mean follow‐up duration was 38 ± 8 month (at least 36 month and up to 53 month). The 3‐year MACE rate did not show a significant difference between the two groups [52 (12.1%) in SES vs. 29 (14.1%) in PES, P = 0.496]. The definite and probable ST at 3 year were similar in both SES and PES [12 (2.8%) in SES vs. 7 (3.4%) in PES, P = 0.681]. There were no differences in hazard ratio for MACE and ST between two stents [MACE, crude: 0.844 (0.536–1.330) and adjusted for PS: 0.858 (0.530–1.389); ST, crude: 0.820 (0.323–2.083) and adjusted for PS: 0.960 (0.357–2.587)]. Conclusions: The present study demonstrated that long‐tem cardiac outcomes including ST were not significantly different between SES and PES in patients with DM. © 2008 Wiley‐Liss, Inc. |
| |
Keywords: | diabetes sirolimus paclitaxel stents coronary stenosis |
|
|